Patents by Inventor Andre Goy

Andre Goy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) as biomarkers for poor outcome Hodgkin lymphoma patients
    Patent number: 9506118
    Abstract: The described invention comprises methods for predicting recurrence of Hodgkin Lymphoma (HL) and poor clinical outcome in a Hodgkin Lymphoma (HL) subject. The methods comprise providing a sample from the HL subject and a sample from a good clinical outcome control subject; isolating total RNA comprising Fibroblast Growth Factor-2 (FGF2) and Syndecan-1 (SDC1) RNA from the sample from the HL subject and from the sample from the good clinical outcome control subject; amplifying the total RNA; measuring a level of expression of the FGF2 and the SDC1 RNA in the HL subject and in the good clinical outcome control subject; and comparing the level of expression of the FGF2 and the SDC1 RNA expressed by the HL subject with the level of expression of the FGF2 and the SDC1 RNA expressed by the good clinical outcome control subject.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: November 29, 2016
    Assignee: Hackensakc University Medical Center
    Inventors: K. Stephen Suh, Andre Goy
  • FIBROBLAST GROWTH FACTOR-2 (FGF2) AND SYNDECAN-1 (SDC1) AS BIOMARKERS FOR POOR OUTCOME HODGKIN LYMPHOMA PATIENTS
    Publication number: 20150252433
    Abstract: The described invention comprises methods for predicting recurrence of Hodgkin Lymphoma (HL) and poor clinical outcome in a Hodgkin Lymphoma (HL) subject. The methods comprise providing a sample from the HL subject and a sample from a good clinical outcome control subject; isolating total RNA comprising Fibroblast Growth Factor-2 (FGF2) and Syndecan-1 (SDC1) RNA from the sample from the HL subject and from the sample from the good clinical outcome control subject; amplifying the total RNA; measuring a level of expression of the FGF2 and the SDC1 RNA in the HL subject and in the good clinical outcome control subject; and comparing the level of expression of the FGF2 and the SDC1 RNA expressed by the HL subject with the level of expression of the FGF2 and the SDC1 RNA expressed by the good clinical outcome control subject.
    Type: Application
    Filed: March 6, 2015
    Publication date: September 10, 2015
    Inventors: K. Stephen Suh, Andre Goy